Platelet Rich Plasma (PRP) - Market Insights, Competitive Landscape, and Market Forecast - 2030

Platelet Rich Plasma (PRP) Market By Product Type (PRP Systems And PRP Kits), By PRP Type (Pure Platelet Rich Plasma, Leukocyte Rich Plasma, And Others), By Application (Orthopedic, Sports Medicine, Cosmetic Surgery, And Others), By End-User (Hospitals, Clinics, And Others), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to the rising demand of platelet-rich plasma (PRP) therapy in various therapeutic applications and the increasing demand for non-surgical and minimally invasive therapy

Global platelet rich plasma (PRP) market was valued at USD 413 million in 2023, growing at a CAGR of 10.18% during the forecast period from 2024 to 2030 to reach USD 736 million by 2030. The demand for platelet rich plasma (PRP) is primarily being boosted by the increasing figures of patients suffering from orthopedic diseases, sports injuries, acute and chronic wounds, gynecological diseases, urological diseases, among other. In addition, the growing need of PRP in various aesthetic procedures such as cosmetic facials, facial rejuvenation, acne scars, facial scarring, facelift and rhytidectomy, rhinoplasty, hair restoration, fat grafting, and other aesthetic procedures, the increasing product launches and approval among others are thereby contributing to the overall growth of the platelet rich plasma (PRP) market during the forecast period from 2024-2030.

Platelet Rich Plasma (PRP) Market Dynamics:

The platelet rich plasma (PRP) market is witnessing a growth in product demand owing to various factors, one of the key factors being the increase in the prevalence of various therapeutic indications.

As per the International Osteoporosis Foundation (2023), over 8.9 million fractures related to osteoporosis occurs annually worldwide. It further stated that about one in five men and one in three women over the age of 50 are susceptible to suffer from a fracture due to weak bones.

Furthermore, as per the data published by the Osteoarthritis Action Alliance (OAAA), 2020, in the year 2019, about 242 million people worldwide suffered from symptomatic and activity limiting osteoarthritis (OA) which is one of the common types of arthritis. The data also mentioned that about 43% of people with OA are 65 or older and 88% of people with OA are 45 or older in 2019.

PRP can be used to treat osteoporosis, and can effectively manage pain in orthopedic disorders. Thus, the increasing prevalence of various orthopedic disease such as arthritis, tennis elbow, golfer's elbow, plantar fasciitis, rotator cuff injuries, and others, will increase the demand of PRP therapy, ultimately increasing the demand of PRP systems and kits used while doing PRP therapy.

The American Academy of Dermatology Association in a latest data stated that acne is the most common skin condition in the United States, affecting up to 50 million people annually. Also, according to International society of Aesthetic Plastic surgery 2022, nearly 20,128 rhinoplasty surgeries and 23,125 face fat grafting surgical procedures were performed in Japan, in 2022. The afore-said source also mentioned that approximately 16,776 rhinoplasty and 9,828 fat grafting surgeries were done in Spain, in 2022.

PRP therapy in case of fat grafts offers a better fat grafting survival, a less bruising and inflammation reaction, and easier application of fat grafts. Also, platelets rich plasma (PRP) is claimed to fasten healing process reducing postoperative edema, and bleeding, thus it have a wide application in various cosmetic procedures. Thus, the growing demand of PRP in various aesthetic procedures such as cosmetic facials, facial rejuvenation, acne scars, facial scarring, facelift and others, will create a positive impact on the market of platelet-rich plasma in the upcoming years.

Along with the facial procedures, PRP is also widely used for hair restoration. PRP can be used as a new therapeutic option for hair loss including androgenetic alopecia and female pattern hair loss, either as a monotherapy or an adjuvant to conventional therapy or hair transplantation.

Therefore, the above-mentioned factors are contributing to the growth of the platelet rich plasma (PRP) market during the forecast period from 2024-2030.

However, the presence of alternative treatment options, multiple session, leading to high cost of therapy, and others may restrict the platelet rich plasma (PRP) market growth.

The platelet rich plasma (PRP) market was significantly impacted during the period of COVID- 19 pandemic. The outbreak of the pandemic led to the cancellation of outpatient visits and the suspension of non-emergency hospitalization and treatment procedures for various ailments such as orthopedic and sports injuries, gynecological, urological, cosmetic, and others. This resulted in the reduced number patients of routine treatments of the above mentioned disorders. Moreover, many elective surgeries were postponed as treatment of patients suffering from coronavirus infection was on priority. Additionally, the restrictions in supply chain, raw materials, and other resources halted the manufacturing of devices, leading to the shortage of devices and kits in the market. However, the vaccine development of COVID-19 initiated the process of economic recovery. Also, with the easing of lockdown restrictions and the return of normalcy in the economic landscape initiated the process of resumption of regular healthcare services such as outpatients visits for various treatments, therapies, and surgeries for the afore-mentioned ailments, thereby bringing the demand for products on track in the platelet rich plasma (PRP) market.

Platelet Rich Plasma (PRP) Market Segment Analysis:

Platelet Rich Plasma (PRP) Market by Product Type (PRP Systems and PRP Kits), PRP Type (Pure Platelet Rich Plasma, Leukocyte Rich Plasma, and Others), Application (Orthopedic, Sports Medicine, Cosmetic Surgery, and Others), End-User (Hospitals, Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the platelet rich plasma (PRP) market, the PRP systems category is expected to amass significant revenue share of 60% in the year 2023 growing at a CAGR of 10.46% during the forecast period from 2024-2030. This can be ascribed to the advantages and applications associated with PRP systems.

The commercially available PRP systems facilitate the preparation of ready to apply platelet-rich suspensions in a reproducible manner. These systems operate on a small volume of drawn blood and on the principle of centrifugation.

Depending on the method and time of its centrifugation, these systems differ widely in their ability to collect and concentrate platelets.

The PRP systems help to prepare suspensions of different concentration of platelets and leucocytes. For example, Arthrex ACP, a double-syringe system facilitate the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient's point of care. The prepared PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as per the need.

Also, the SmartPrep® 3 System by Terumo Corporation is used for producing autologous platelet-rich plasma (PRP) enriched with growth factors. The system has features such as cell capture technology, optimized platelet recovery, consistent results, high platelet concentrations, fast processing time, and volume flexibility.

The increasing technological advancements such as automation of PRP systems is likely to increase their demand. For instance, Angelina is the first completely automated blood centrifuge for autologous PRP generation developed by 2M Engineering. This device does full automatic concentration and extraction of thrombocyte or platelets from whole blood for a range of potential medical applications.

Therefore, the advantages offered by the PRP systems are predicted to contribute to the increasing demand for this product type thereby driving the growth of the overall platelet rich plasma (PRP) market during the forecast period.

North America is expected to dominate the overall Platelet Rich Plasma (PRP) Market:

Among all the regions, North America is estimated to account for the largest share of 43% in the platelet rich plasma (PRP) market in the year 2023. Owing to the factors such as the rising geriatric population, the growing incidents of traumatic injuries due to falls, accidents, and others, the growing number of orthopedic and cosmetic procedures, along with recent product launches in the region, the demand for PRP is expected to increase during the forecast period. Moreover, the rising physician and patient awareness about newly introduced treatment procedures and technologies, are expected to aid in the growth of the North America PRP market. Furthermore, high disposable income, sophisticated healthcare infrastructure, regulatory approval for new devices, and high awareness about ophthalmic diseases also helped the market growth in this region.

For instance, as per a report by the Centers for Disease Control and Prevention (CDC) (2023), more than 32.5 million people were affected with osteoarthritis in 2019, and is one of the most common form of joint disorders in the United States.

The American Academy of Orthopedic Surgeons, stated that each year, almost 2 million people in the United States visit doctors because of rotator cuff (RC) tears. In case of RC tear, PRP injections encourages the body's healing processes and rally the growth factors to increase regenerative capability at the place of injection.

Coupled with the factors mentioned above, strategic activities such as product launches and approvals, mergers, acquisitions, partnerships, and others also help in boosting regional product demand. For instance, in February 2023, Royal Biologics, a company specializing in Advanced Cellular Technologies & Enhanced Autologous Solutions, announced the commercial launch of BIOINCYTE(TM) PRFM, a next-generation PRP system, which converts traditional PRP to Platelet Rich Fibrin Matrix (PRFM) formulations. Thus, such strategic steps help to increase the demand for platelet rich plasma (PRP), thereby driving the North America platelet rich plasma (PRP) market forward during the forecast period.

Platelet Rich Plasma (PRP) Market Key Players:

Some of the key market players operating in the platelet rich plasma (PRP) market include Johnson & Johnson, Zimmer Biomet, Arthrex, Terumo Corporation, Stryker, Dr. PRP USA LLC., Juventix Regenerative Medical, LLC., EmCyte Corporation, Apex Biologix, Celling Biosciences, Isto Biologics, Exactech, Inc., Nuo Therapeutics, Inc., Regen Lab SA, CollPlant Biotechnologies Ltd., Estar Technologies Ltd., ELTEK S.P.A., Royal Biologics, PRP Concepts, Crown, and others.

Recent Developmental Activities in the Platelet Rich Plasma (PRP) Market:

In October 2022, i-Stem PRP Kit Platelet Rich Plasma Therapy was launched in the UK, which is a unique, modernized anti-shake patented i-Stem PRP System, for the safe and effective treatment within the exciting field of regenerative medicine, making treatment effective and simple.

In September 2022, Royal Biologics, an ortho-biologics company focused on Autologous and Live Cellular solutions, announced FDA 510K approval of their Maxx- PRP concentration system. The system is a patented next-generation concentration device that can be used to concentrate autologous whole blood for the safe and rapid preparation of platelet-rich plasma to use point of care for mixing with autograft and/or allograft to improve handling characteristics.

In February 2020, EmCyte, the world leader in platelet rich plasma and progenitor stem cell biologics, announced FDA 510(k) clearance for its PurePRP® Supraphysiologic Concentrating System for platelet rich plasma. The system is cleared to be used for the safe and rapid preparation of autologous platelet rich plasma (PRP) extracted from sample of blood at the patient's point of care.

Key Takeaways from the Platelet Rich Plasma (PRP) Market Report Study

Market size analysis for current platelet rich plasma (PRP) market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the platelet rich plasma (PRP) market.

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global platelet rich plasma (PRP) market.

Various opportunities available for the other competitor in the platelet rich plasma (PRP) market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current platelet rich plasma (PRP) market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for platelet rich plasma (PRP) market growth in the coming future?

Target Audience who can be benefited from this Platelet Rich Plasma (PRP) Market Report Study

Platelet rich plasma (PRP) products providers

Research organizations and consulting companies

Platelet rich plasma (PRP)-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in platelet rich plasma (PRP)

Various End-users who want to know more about the platelet rich plasma (PRP) market and the latest technological developments in the platelet rich plasma (PRP) market.

Frequently Asked Questions for the Platelet Rich Plasma (PRP) Market:

1. What is platelet rich plasma (PRP)?

Platelet-rich plasma (PRP) is an autologous conditioned plasma product derived from peripheral blood with inherent immunomodulatory and anabolic properties.

2. What is the market for global platelet rich plasma (PRP)?

Global platelet rich plasma (PRP) market was valued at USD 413 million in 2023, growing at a CAGR of 10.18% during the forecast period from 2024 to 2030 to reach USD 736 million by 2030.

3. What are the drivers for global platelet rich plasma (PRP) market?

The demand for platelet rich plasma (PRP) is primarily being heightened by the increasing prevalence of various therapeutic diseases such as orthopedic, gynecological, urological, and others. In addition, the surging demand of non-surgical and non-invasive surgeries across the globe, the increasing number of aesthetic procedures using PRP therapy, increasing product launches and approvals, among others, thereby contribute to the overall growth of the platelet rich plasma (PRP) market during the forecast period from 2024-2030.

4. Who are the key players operating in the global platelet rich plasma (PRP) market?

Some of the key market players operating in the platelet rich plasma (PRP) market include Johnson & Johnson, Zimmer Biomet, Arthrex, Terumo Corporation, Stryker, Dr. PRP USA LLC., Juventix Regenerative Medical, LLC., EmCyte Corporation, Apex Biologix, Celling Biosciences, Isto Biologics, Exactech, Inc., Nuo Therapeutics, Inc., Regen Lab SA, CollPlant Biotechnologies Ltd., Estar Technologies Ltd., ELTEK S.P.A., Royal Biologics, PRP Concepts, Crown, and others.

5. Which region has the highest share in the platelet rich plasma (PRP) market?

North America is expected to dominate the overall Platelet Rich Plasma (PRP) market during the forecast period from 2024-2030. Factors such as the upsurge in the ageing population susceptible to various disorders, rise in the number of osteoporosis cases, growing number of cosmetic surgeries, among others will positively impact the North American Platelet Rich Plasma (PRP) market. Furthermore, high disposable income, sophisticated healthcare infrastructure, regulatory approval for new devices, and high awareness about PRP therapy also helped the market growth in this region.